COMP <GO>
VMD vs MRK // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Viemed Healthcare Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: VMD 5
— MRK 8
■ METRIC PARITY
LAST: $9.95 (-0.40%) • MKT CAP: $379.0M
options-implied-move
—
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VMD VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VMD | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 57.50% | 74.80% | -17.30 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.00% | 20.70% | -7.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.6x | 15.3x | -8.70 | VMD | /valuation <GO> |
| Free Cash Flow Yield | 3.15% | 3.42% | -0.27 | MRK | /fcf-yield <GO> |
| Operating Margin | 8.50% | 34.30% | -25.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | 5.70% | 28.10% | -22.40 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 20.50% | 1.30% | +19.20 | VMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.59 | 5.19 | +1.40 | VMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | VMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.0 | 51.7 | +8.30 | VMD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.7x | 18.4x | +2.30 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $379.0M | $361.02B | -$360.64B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VMD REV | MRK REV | VMD GROSS % | MRK GROSS % | VMD FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $270.3M | $65.01B | 57.5% | 74.8% | $11.9M | $12.36B |
| FY 2024 | $224.3M | $64.17B | 59.4% | 76.3% | $1.3M | $18.10B |
| FY 2023 | $183.0M | $60.12B | — | — | $45.2M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VMD // BETA —
MRK // BETA 0.92